

San Diego Dermatology Symposium 2021

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Interim Analysis of a Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent

Author COI Statement

All authors are clinical trial investigators for or employees of Dermavant Sciences, Inc. Bruce Strober is an investigator for AbbVie, Cara, Corrona Psoriasis Registry, Dermira, and Novartis; is a consultant with honoraria for AbbVie, Ammirall, Amgen, Arcutis, Arena, Aristeia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant Sciences, Inc., Dermira, Eli Lilly, Equillum, GlaxoSmithKline, Janssen, LEO Pharma, Meiji Seika Pharma, Mindera, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharma, Sanofi-Genzyme, and UCB; and is a speaker for AbbVie, Amgen, Eli Lilly, Janssen, and Ortho Dermatologics; and has received consultancy fees from Corrona Psoriasis Registry; and is Editor-in-Chief with honorarium for the Journal of Psoriasis and Psoriatic Arthritis. Robert Bissonnette is a consultant and has received grants from AbbVie; and holds stock options in Innovaderm Research. April Armstrong has received grants from AbbVie, Bristol Meyers Squibb, Dermavant Sciences, Inc., Dermira, Eli Lilly, Galderma, Kyowa Hakko Kirin, LEO Pharma, Novartis, Pfizer, Regeneron, and UCB; and personal fees from AbbVie, Bristol Myers Squibb, Celgene, Dermavant Sciences, Inc., Dermira, Eli Lilly, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Janssen, LEO Pharma, Menlo Therapeutics, Merck, Modernizing Medicine, Novartis, Ortho Dermatologics, Regeneron, Sanofi Genzyme, Science 37 Inc., Sun Pharma, UCB, and Valeant. Linda Stein Gold is a consultant for Arcutis, Amgen, Bristol Meyers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma; has received grants from Arcutis, Amgen, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, and Ortho Dermatologic; has received payment for development of educational presentations from Amgen, LEO Pharma, and Ortho Dermatologic. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Ammirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. Leon Kircik is a consultant for Dermavant Sciences, Inc. Benjamin Ehst is an investigator for AbbVie, Bristol Myers Squibb, Eli Lilly, Evelo Biosciences, Janssen, Novartis, Ortho Dermatologic, Pfizer, Sun Pharma and UCB; and a consultant for Eli Lilly, Evelo Biosciences, Janssen, Novartis, Ortho Dermatologic; and has received speaker honoraria from Eli Lilly, Novartis, Ortho Dermatologic, The National Psoriasis Foundation (non-profit). Philip M Brown, and Anna M Tallman are employees of Dermavant Sciences, Inc. with stock options. Mark Lebwohl receives research funds from AbbVie, Amgen, Arcutis, Inc., Boehringer Ingelheim, Dermavant Sciences, Inc., Eli Lilly, Incyte, Janssen Research & Development, LLC, Leo Pharmaceuticals, Orth Dermatologics, Pfizer, and UCB, Inc. Dr Lebwohl is also a consultant for Aditum Bio, Allergan, Ammirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD Skincare, Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Inc., EMD Serono, Evelo Therapeutics, Evommune, Inc., Helsinn Therapeutics, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Prominus/Dr. Reddy's Laboratories, Theravance, and Verrica.